A Look at the Key Issues Driving Growth in the Asian Cardiovascular Market

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 29, 2006--Research and Markets
(http://www.researchandmarkets.com/reports/c31685) has announced the
addition of The Asian Cardiovascular Market Outlook to 2010 to their
offering.


The Asian Cardiovascular Market Outlook to 2010 is a new management
report which provides comprehensive coverage of the major
cardiovascular markets in the Asia Pacific region. This report
provides detailed analysis of, market trends, epidemiology, current
leading brands of treatment, product sales forecast and future market
leaders over the period 2005-2010 in nine markets: China, India,
Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and
Taiwan.

The Asia Pacific region is an important market for cardiovascular
products; it is estimated to have high prevalence rates for
cardiovascular diseases and associated risk factors. However, due to
the increasing presence of effective generic medicine and the limited
launches of innovative, the threat of underperformance facing major
pharmaceutical companies is now very real.

Through analysis and forecasts, this report will allow you to identify
the cardiovascular market trends in developed and emerging Asian
countries, assess the dominant forces driving market growth and
develop potential growth and diversification opportunities in this
region over the period 2005-2010.

Geographic coverage...

- China - India - Indonesia - Malaysia - Singapore - South Korea
-Taiwan - Thailand - The Philippines

Risk factors covered

- Hypertension - Dyslipidemia - Diabetes

Must have' statistics and analysis in this report

This report provides:

-- Epidemiological analysis and forecast prevalence of the major
cardiovascular indications and their sub-indications over the period
2005-10 in the Asia Pacific region.

-- Historical analysis of the performance of leading products in the
four therapy areas under study.

-- Company analysis and market share of the top eight players in the
cardiovascular area: Pfizer, Sanofi-Aventis, AstraZeneca, Merck,
Novartis, Bayer, Roche and GSK.

-- Detailed analysis of forecast potential products in the
cardiovascular area of the Asia Pacific region.

-- Head to head performance analysis of leading pharmaceutical
corporations and company forecasts to 2010.

Your questions answered

-- What will be the major growth indications in the cardiovascular
market over the period 2005-10 in the Asia Pacific region?

-- In the Asia Pacific markets, which companies were the winners and
losers in the cardiovascular area in 2004?

-- How have recent major launches from Pfizer, Sanofi-Aventis,
AstraZeneca and Merck performed in the Asia Pacific region?

-- In the Asia Pacific region, which companies will become the key
players in the cardiovascular area over the period 2005-10?

-- Which products will be impacted by generic competition over the
period 2005-10 in the Asia Pacific market?

-- Which pipeline products, in the Asia Pacific region, will be the
growth drivers of the future and why?

-- Which indications in the Asia Pacific market are forecast to have
the highest levels of market potential over the period 2005-10?

-- What will the competitive landscape in hypertension, thrombosis and
dyslipidemia look like in 2010?

Actionable strategies to drive your profits forward

-- Save time and money in research with the report's insightful
qualitative and quantitative coverage of: the major cardiovascular
indications; the Asia Pacific pharmaceutical markets; and, the eight
largest companies currently active in the cardiovascular market.

-- Quick and comprehensive understanding of how recent events are
affecting the performance of major products, and how their marketers
are confronting competitive changes in the cardiovascular marketplace.

-- Gain up-to-date competitive intelligence across the cardiovascular
portfolio and understand the major issues affecting key pharmaceutical
marketers and product development.

-- Understand which cardiovascular indications have the greatest
potential to catalyze franchise growth, and how the pharmaceutical
industry is attempting to effectively utilize these opportunities.

-- Compare the franchises of top pharmaceutical marketers across the
major indications, and understand how market share of leading
companies will change over the next 5 years.

Topics Covered

Executive Summary

Chapter 1 Patient potential

Chapter 2 Regional healthcare and licensing trends

Chapter 3 Regional market analysis

Cardiac therapies sales forecasts

Chapter 4 Key players in the Asian cardiovascular market

Chapter 5 Appendix

List of Figures

List of Tables

Companies Mentioned

- Pfizer - Sanofi-Aventis - Merck & Co - AstraZeneca - Novartis -
Bayer - GSK - Roche

For more information visit http://www.researchandmarkets.com/reports/c31685